Skip to main content

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

D-Mongolia: screening and linkage-to-care for Hepatitis D in Mongolian nationals living in Spain - Modalitat hepatitis

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 48763
Reference: GLD21_00139
Duration: 30/06/2022 - 31/10/2024

Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis delta.

IP: Maria Buti Ferret
Collaborators: Maria Jose Herrero Mata, Ana Barreira Diaz, Maria del Mar Riveiro Barciela, Jordi Llaneras Artigues, Adriana Palom Agusti
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI20/01692
Duration: 01/01/2021 - 30/06/2025

No hepatitis B infections without linkage to treatment: research in a large health area of Barcelona

IP: Maria Buti Ferret
Collaborators: -
Funding agency: Gilead Sciences, Inc.
Funding: 125537.02
Reference: GLD20_IN-ES-320-6107_HBV2020
Duration: 13/09/2021 - 12/09/2023

Desarrollo de un test rápido de diagnóstico precoz de hepatocarcinoma en biopsia líquida, usando PCR en tiempo real y secuenciación masiva.

IP: Maria Buti Ferret
Collaborators: Elena Vargas Accarino, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: FI18/00027
Duration: 01/01/2019 - 13/04/2023

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Anna Sanjuan Viaplana

Anna Sanjuan Viaplana

Medium Grade Technician
Statistics and Bioinformatics Unit (UEB)
Preclinical Core Facilities
External Strategy Directorate
Read more
Garcia Blanco, Alejandra

Garcia Blanco, Alejandra

Research technician
Neurodegenerative Diseases
Read more
Joan Compte Barrón

Joan Compte Barrón

Predoctoral researcher
Neurodegenerative Diseases
Read more
Piqué Ponti, Julia

Piqué Ponti, Julia

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.